Edition:
Deutschland

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

100.68USD
3 Aug 2020
Change (% chg)

$0.04 (+0.04%)
Prev Close
$100.64
Open
$101.20
Day's High
$101.55
Day's Low
$100.22
Volume
940,766
Avg. Vol
1,890,312
52-wk High
$102.89
52-wk Low
$61.62

Select another date:

Mon, Jul 27 2020

Photo

The U.S. has more COVID-19 testing than most. So why is it falling so short?

The United States might have more COVID-19 testing capacity than any other country. So why have we seen laboratories overwhelmed and many patients again waiting a week or more for results?

Photo

The U.S. has more COVID-19 testing than most. So why is it falling so short?

The United States might have more COVID-19 testing capacity than any other country. So why have we seen laboratories overwhelmed and many patients again waiting a week or more for results?

INSIGHT-The U.S. has more COVID-19 testing than most. So why is it falling so short?

* Labs rely on automated testing machines from a few companies

HCA Healthcare posts surprise profit as elective surgery demand improves

HCA Healthcare Inc reported a surprise quarterly profit on Wednesday, as the U.S. hospital operator saw a gradual pickup in demand for elective surgeries amid easing of coronavirus-led restrictions in some parts of the country.

UPDATE 2-HCA Healthcare posts surprise profit as elective surgery demand improves

July 22 HCA Healthcare Inc reported a surprise quarterly profit on Wednesday, as the U.S. hospital operator saw a gradual pickup in demand for elective surgeries amid easing of coronavirus-led restrictions in some parts of the country.

HCA Healthcare quarterly profit jumps nearly 38% on government stimulus

July 22 HCA Healthcare Inc reported a nearly 38% rise in second-quarter profit on Wednesday, as the hospital operator received $822 million in government stimulus income related to the Coronavirus Aid, Relief, and Economic Security (CARES) Act.

Photo

Abbott sees no hit to demand for COVID-19 tests from vaccine

Abbott Laboratories said on Thursday demand for its coronavirus tests will likely remain high even after a safe and effective vaccine is available as the medical device maker forecast full-year profit above analysts' estimates.

Abbott CEO expects high demand for antibody tests even after approved COVID-19 vaccine

Abbott Laboratories expects to see higher demand for serology and antibody testing for the new coronavirus, even after a vaccine becomes available, Chief Executive Officer Robert Ford said on a post-earnings conference call on Thursday.

Photo

Abbott sees no hit to demand for COVID-19 tests from vaccine

Abbott Laboratories said on Thursday demand for its coronavirus tests will likely remain high even after a safe and effective vaccine is available as the medical device maker forecast full-year profit above analysts' estimates.

Abbott CEO expects high demand for antibody tests even after approved COVID-19 vaccine

Abbott Laboratories expects to see higher demand for serology and antibody testing for the new coronavirus, even after a vaccine becomes available, Chief Executive Officer Robert Ford said on a post-earnings conference call on Thursday.

Select another date: